What is William Blair’s Estimate for SRPT Q4 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at William Blair issued their Q4 2025 earnings per share estimates for Sarepta Therapeutics in a report released on Monday, January 27th. William Blair analyst S. Corwin expects that the biotechnology company will post earnings of $3.60 per share for the quarter. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.49 per share.

Several other research analysts have also recently weighed in on the company. Guggenheim raised their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. Royal Bank of Canada restated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. Raymond James reiterated an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Stock Down 0.6 %

Shares of SRPT stock opened at $113.72 on Thursday. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The business’s fifty day moving average is $122.80 and its 200-day moving average is $127.23. The stock has a market cap of $10.86 billion, a PE ratio of 90.98 and a beta of 0.77.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently made changes to their positions in the business. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $4,771,000. Simplify Asset Management Inc. lifted its stake in shares of Sarepta Therapeutics by 84.6% in the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after buying an additional 88,474 shares during the period. Geode Capital Management LLC raised its holdings in Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after acquiring an additional 44,306 shares in the last quarter. Summit Partners Public Asset Management LLC grew its holdings in shares of Sarepta Therapeutics by 547.9% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Finally, Larson Financial Group LLC raised its stake in shares of Sarepta Therapeutics by 1,649.8% in the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock valued at $1,093,000 after purchasing an additional 8,249 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.